The latest price target for Capricor Therapeutics (NASDAQ:CAPR) was reported by B. Riley Securities on March 13, 2026. The analyst firm set a price target for $63.00 expecting CAPR to rise to within 12 months (a possible 96.20% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Capricor Therapeutics (NASDAQ:CAPR) was provided by B. Riley Securities, and Capricor Therapeutics maintained their buy rating.

There is no last upgrade for Capricor Therapeutics

There is no last downgrade for Capricor Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on March 13, 2026 so you should expect the next rating to be made available sometime around March 13, 2027.

While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a maintained with a price target of $50.00 to $63.00. The current price Capricor Therapeutics (CAPR) is trading at is $32.11, which is out of the analyst’s predicted range.